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Abstract
Six 3′R,4′R-di-O-(S)-camphanoyl-2′,2′-dimethyldihydropyrano[2,3-f]chromone (DCP) and two
3′R,4′R-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) derivatives were designed, synthesized,
and evaluated for inhibition of HIV-1NL4-3 replication in TZM-bl cells. 2-Ethyl-2′-monomethyl-1′-
oxa- and -1′-thia-DCP (5a, 6a), as well as 2-ethyl-1′-thia-DCP (7a) exhibited potent anti-HIV
activity with EC50 values of 30, 38 and 54 nM and therapeutic indexes of 152.6, 48.0 and 100.0,
respectively, which were better than or comparable to those of the lead compound 2-ethyl-DCP in
the same assay. 4-Methyl-1′-thia-DCK (8a) also showed significant inhibitory activity with an
EC50 of 128 nM and TI of 237.9.
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In our previous research, 3′R,4′R-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK, 1, Fig. 1)
demonstrated extremely potent inhibitory activity against HIV-1 replication in H9
lymphocytic cells.1 Subsequently, hundreds of DCK and some of its ring-A positional
isomer DCP (3′R,4′R-di-O-(S)-camphanoyl-2′,2′-dimethyl-dihydro-pyrano[2,3-f]chromone,
2, Fig. 1) derivatives have been designed, synthesized and screened for anti-HIV activity in
H9 lymphocytes, MT-2 cell lines, and MT-4 cell lines.2–8 4-Methyl-DCK (3, Fig.1) and 2-
ethyl-DCP (4, Fig.1) showed the most promising anti-HIV results in these two series.
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Structure-activity relationship (SAR) studies found that DCP derivatives exhibited better
anti-HIV activity than the corresponding DCKs;8 2′-α-monomethyl-4-methyl DCK
derivatives were more potent than 2′-gem-dimethyl DCKs;9 bio-isosteric analogues with a
sulfur rather than oxygen in the ring-C of DCK exhibited remarkable inhibitory effects on
HIV-1 replication;9,10 and a 3′,4′-dicamphanoyl moiety is indispensable for anti-HIV
activity.11 Considering these SAR research results, we have now designed and synthesized
2′-monomethyl-DCP (5, 1′-oxa; 6, 1′-thia), 2-ethyl-1′-thia-DCP (7), and 4-methyl-1′-thia-
DCK (8) analogues to further explore the pharmacophores of the 2′-position and the
bioisosteric effect at the 1′-position. This paper reports their synthesis and anti-HIV bioassay
data.
The synthetic routes to 5a, 5b, 6a and 6b are shown in Scheme 1. The intermediate 2-
ethyl-7-mercapto-4H-chromen-4-one (12) was obtained by reacting 2-ethyl-7-hydroxy-4H-
chromen-4-one (9) with dimethylthiocarbamoyl chloride in EtOH in the presence of
anhydrous potassium carbonate, followed by a rearrangement at 240 °C, then hydrolysis
with methanolic KOH and acidification with HCl. Compounds 9 and 12 were treated with 3-
chloro-1-butyne in dimethyl formamide (DMF) or acetone in the presence of anhydrous
potassium carbonate and potassium iodide at room temperature to produce the propargyl
ethers 13 and 14, followed by thermal rearrangement in refluxing N,N-diethylaniline to form
intermediates 15 and 16. Sharpless dihydroxylation (AD) of 15 and 16 afforded dihydroxy
derivatives 17a/17b and 18a/18b, respectively, as diastereoisomeric mixtures. Target
compounds 5a and 5b were obtained by acylation of 17a and 17b with (S)-(−)-camphanic
chloride in CH2Cl2 at room temperature with 4-dimethylaminopyridine (DMAP) as acid
scavenger. Compounds 6a and 6b were synthesized by the same procedure from 18a and
18b. The pure diastereoisomers 5a, 5b, 6a, and 6b were obtained by separation with column
chromatography on silica gel [petroleum ether/ethyl acetate, 3:1 (v/v)].
The preparation of 7a and 7b is illustrated in Scheme 2. 2-Ethyl-7-mercapto-4H-chromen-4-
one (12) was treated with 3-chloro-3-methyl-1-butyne in EtOH/H2O (v/v=1:1) in the
presence of potassium hydroxide at room temperature to produce the propargyl ether 19,
followed by thermal rearrangement in refluxing N,N-diethylaniline to form intermediate 20.
Sharpless AD of 20 afforded dihydroxy derivatives 21a and 21b. Target compounds 7a and
7b were obtained by acylation of 21a and 21b with (S)-(−)-camphanic chloride in CH2Cl2 at
room temperature with DMAP as an acid scavenger. Diastereoisomers 7a and 7b could be
separated by column chromatography on silica gel [petroleum ether/ethyl acetate, 3:1 (v/v)].
The synthesis of 8a and 8b was accomplished by a similar four-step sequence, as depicted in
Scheme 3. Diastereoisomers 8a and 8b were separated by HPLC on an Alltima column (2.1
mm × 150 mm, C-18) with acetonitrile/water 70:30 (v/v) as eluant.
The eight newly synthesized compounds 5–812 were evaluated for anti-HIV activity in
TZM-bl cells in parallel with 2-ethyl-DCP.13 The bioassay data are summarized in Table 1.
Compounds 5a, 6a, and 7a showed significant anti-HIV activity with EC50 values of 30, 38
and 54 nM, which were better than the reference compound (2-ethyl-DCP, EC50: 120nM),
and had good therapeutic index (TI) values of 152.6, 48.0 and 100.0, respectively. With a
two-fold lower EC50 value, 2-ethyl-1′-thia-DCP (7a) was more potent than 4-methyl-1′-thia-
DCK (8a). This result was coincident with the previous activity comparison between the
DCP and DCK series, e.g. 2-ethyl DCP was more active than 4-methyl DCK.8 2′-
Monomethyl-2-ethyl-1′-oxa- (5a) and -1′-thia-DCP derivatives (6a) exhibited better anti-
HIV activity than the corresponding 2′-gem-dimethyl substituted compounds 2-ethyl-DCP
and 7a. Interestingly, 5b, 6b, 7b and 8b exhibited remarkably reduced or even completely
abolished anti-HIV activity, consistent with the results from prior compounds. This finding
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suggested that, just as in the DCK series, the spatial orientations of the 2′-methyl group and
the 3′,4′-dicamphanoyls are also crucial to anti-HIV activity in DCP analogues.
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12. Analytical data of target compounds 5–8: Configuration assignments of isomeric compound pairs
were based on prior data in reference 9.5a. mp 138–141°C; 1H NMR (CDCl3, 400 MHz) δ 0.95–
1.12 (18H, m, 6×-CH3 in camphanoyl), 1.67–2.50 (8H, m, 4×-CH2 in camphanoyl), 1.24 (3H, t, -
CH3 in ethyl), 1.48 (3H, d, J = 6.3 Hz, 2′-CH3), 2.56 (2H, m, -CH2 in ethyl), 4.55 (1H, m, 2′-CH),
5.17 (1H, m, 3′-H), 6.14 (1H, s, 3-H), 6.80 (1H, d, J = 3.1 Hz, 4′-H), 6.93 (1H, d, J = 9.0 Hz, 6-H),
8.12 (1H, d, J = 9.0 Hz, 5-H). [α]D −37 (c 0.1, CHCl3). HRMS(MALDI-DHB): Calcd. for
C35H40O11: 636.2571; Found: 637.2643 [M+H+]. 5b. mp 203–206°C; 1H NMR (CDCl3, 400
MHz) δ 0.85 (3H, s, -CH3 in camphanoyl), 1.02–1.13 (15H, m, -CH3×5 in camphanoyl), 1.68–
2.41 (8H, m, 4×-CH2 in camphanoyl), 1.29 (3H, t, -CH3 in ethyl), 1.47 (3H, d, J = 6.3 Hz, 2′-
CH3), 2.47 (2H, m, -CH2 in ethyl), 4.66 (1H, m, 2′-CH), 5.29 (1H, m, 3′-H), 6.14 (1H, s, 3-H),
6.81 (1H, d, J = 3.5 Hz, 4′-H), 6.92 (1H, d, J = 8.6 Hz, 6-H), 8.11 (1H, d, J = 9.0 Hz, 5-H). [α]D
+81 (c 0.1, CHCl3). HRMS(MALDI-DHB): Calcd. for C35H40O11: 636.2571; Found: 637.2643
[M+H+]. 6a. mp 175–178°C; 1H NMR (CDCl3, 400 MHz) δ 0.98–1.13 (18H, m, 6×-CH3 in
camphanoyl), 1.68–2.59 (8H, m, 4×-CH2 in camphanoyl), 1.25 (3H, t, -CH3 in ethyl), 1.37 (3H, d,
J = 6.7 Hz, 2′-CH3), 2.47 (2H, m, -CH2 in ethyl), 3.87 (1H, m, 2′-CH), 5.32 (1H, m, 3′-H), 6.15
(1H, s, 3-H), 6.97 (1H, d, J = 2.7 Hz, 4′-H), 7.12 (1H, d, J = 8.6 Hz, 6-H), 8.05 (1H, d, J = 8.6 Hz,
5-H). [α]D −272 (c 0.1, CHCl3). HRMS(MALDI-DHB): Calcd. for C35H40O10S: 675.2240 [M
+Na+]; Found: 675.2234 [M+Na+]. 6b. mp 152–155°C; 1H NMR (CDCl3, 400 MHz) 0.82–1.13
(18H, m, -CH3×6 in camphanoyl), 1.68–2.66 (8H, m, 4×-CH2 in camphanoyl), 1.29 (3H, t, -CH3
in ethyl), 1.38 (3H, d, J = 6.7 Hz, 2′-CH3), 2.44 (2H, m, -CH2 in ethyl), 3.99 (1H, m, 2′-CH), 5.44
(1H, m, 3′-H), 6.16 (1H, s, 3-H), 6.97 (1H, d, J = 2.4 Hz, 4′-H), 7.12 (1H, d, J = 8.7 Hz, 6-H), 8.05
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(1H, d, J = 8.3 Hz, 5-H). [α]D +135 (c 0.1, CHCl3). HRMS(MALDI-DHB): Calcd. for
C35H40O10S: 675.2240 [M+Na+]; Found: 675.2234 [M+Na+]. 7a. mp 249–252°C; 1H NMR
(CDCl3, 400 MHz) δ 0.96–1.76 (24H, 6×-CH3 in camphanoyl, 2×2′-CH3), 1.25 (3H, t, -CH3 in
ethyl), 1.70–2.60 (10H, m, -CH2 in ethyl, 4×-CH2 in camphanoyl), 5.62 (1H, d, J = 4.3 Hz, 3′-
CH), 6.16 (1H, s, 3-H), 6.96 (1H, d, J = 4.3 Hz, 4′-H), 7.11 (1H, d, J = 8.2 Hz, 6-H), 8.06 (1H, d, J
= 8.6 Hz, 5-H). [α]D −130 (c 0.1, CHCl3). HRMS(MALDI-DHB): Calcd. for C36H42O10S:
689.2396 [M+Na+]; Found: 689.2391 [M+Na+]. 7b. mp 188–189°C; 1H NMR (CDCl3, 400 MHz)
δ 0.88–1.76 (24H, 6×-CH3 in camphanoyl, 2×2′-CH3), 1.26 (3H, t, -CH3 in ethyl), 1.60–2.66
(10H, m, -CH2 in ethyl, 4×-CH2 in camphanoyl), 5.71 (1H, d, J = 4.3 Hz, 3′-CH), 6.15 (1H, s, 3-
H), 6.92 (1H, d, J = 4.3 Hz, 4′-H), 7.10 (1H, d, J = 8.6 Hz, 6-H), 8.04 (1H, d, J = 8.2 Hz, 5-H).
[α]D +27 (c 0.1, CHCl3). HRMS(MALDI-DHB): Calcd. for C36H42O10S: 689.2396 [M+Na+];
Found: 689.2391 [M+Na+]. 8a. mp 135–137°C; 1H NMR (CDCl3, 300 MHz) δ 1.11–1.13 (18H,
6×-CH3 in camphanoyl), 1.56–2.53 (8H, m, 4×-CH2 in camphanoyl), 1.38 (3H, s, 2′-CH3), 1.66
(3H, s, 2′-CH3), 2.40 (3H, s, 4-CH3), 5.63 (1H, d, J = 4.5 Hz, 3′-H), 6.18 (1H, d, J = 0.9 Hz, 3-H),
6.76 (1H, d, J = 4.5 Hz, 4′-H), 7.04 (1H, d, J = 8.7 Hz, 6-H), 7.48 (1H, d, J = 8.4 Hz, 5-H). HRMS
(MALDI-DHB) calcd mass for C35H40O10S [M+-H] 651.2269, found 651.2270. 8b. mp 151–
153°C; 1H NMR (CDCl3, 300 MHz) δ 0.87–1.15 (18H, 6×-CH3 in camphanoyl), 1.64–2.64 (8H,
m, 4×-CH2 in camphanoyl), 1.38 (3H, s, 2′-CH3), 1.73 (3H, s, 2′-CH3), 2.40 (3H, d, J = 1.5 Hz, 4-
CH3), 5.69 (1H, d, J = 4.5 Hz, 3′-CH), 6.17 (1H, d, J = 1.5 Hz, 3-H), 6.92 (1H, d, J = 4.5 Hz, 4′-
H), 7.04 (1H, d, J = 8.1 Hz, 6-H), 7.48 (1H, d, J = 8.4 Hz, 5-H). HRMS (MALDI-DHB) calcd
mass for C35H40O10S [M+-H] 651.2269, found 651.2273.
13. HIV-1 infectivity assay:Anti-HIV-1 activity was measured as reductions in Luc reporter gene
expression after a single round of virus infection of TZM-bl cells. HIV-1 at 200 TCID50 and
various dilutions of test samples (eight dilutions, four-fold stepwise) were mixed in a total volume
of 100 μL growth medium in 96-well black solid plates (Corning-Costar). After 48-h incubation,
culture medium was removed from each well and 100 μL of Bright Glo luciferase reagent was
added to each culture well. The luciferase activity in the assay wells was measured using a Victor
2 luminometer. The 50% inhibitory dose (EC50) was defined as the sample concentration that
caused a 50% reduction in Relative Luminescence Units (RLU) compared to virus control wells
after subtraction of background RLU.
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Structures of previously synthesized DCK and DCP analogues (1–4).
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Reagents and conditions: (i) dimethylthiocarbamoyl chloride, EtOH, K2CO3, r.t.; (ii) 240
°C, N2; (iii) KOH, CH3OH, N2, reflux; (iv) 3-chloro-1-butyne, K2CO3, KI in DMF or
acetone, r.t.; (v) N,N-diethylaniline, reflux; (vi) K2OsO2(OH)4, (DHQ)2-PHAL, K3Fe(CN)6,
K2CO3 in t-butanol/H2O (v/v=1:1), ice bath; (vii) (S)-camphanic chloride, DMAP in
CH2Cl2, r.t.
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Reagents and conditions: (i) 3-chloro-3-methyl-1-butyne, KOH, N2, EtOH/H2O (v/v=1:1),
r.t.; (ii) N,N-diethylaniline, reflux; (iii) K2OsO2(OH)4, (DHQ)2-PHAL, K3Fe(CN)6, K2CO3
in t-butanol/H2O (v/v=1:1), ice bath; (iv) (S)-camphanic chloride, DMAP in CH2Cl2, r.t.
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Reagents and conditions: (i) 3-chloro-3-methyl-1-butyne, KOH in EtOH, N2; (ii) N,N-
diethylaniline, reflux; (iii) K2OsO2(OH)4, (DHQ)2-PHAL, K3Fe(CN)6, K2CO3 in t-butanol/
H2O (v/v=1:1), ice bath; (iv) (S)-camphanic chloride, DMAP in CH2Cl2.
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Table 1
Anti-HIV-1 NL4-3 data of analogues 5–8 in TZM-bl cellsa
Compound CC50 (μM) EC50 (μM) TI
5a 4.55 0.030 153
5b - - NS
6a 1.84 0.038 48.0
6b 3.83 0.184 20.8
7a 5.4 0.054 100
7b - - NS
8a >30.6 0.128 >238
8b >30.6 8.59 >3.6
2-Ethyl-DCP 14.3 0.12 119
a
All data presented in this table were averaged from at least three independent experiments. EC50: concentration that inhibits NL4-3 replication by
50%. CC50: concentration that inhibits uninfected TZM-bl cell growth by 50%. TI = CC50/EC50. NS: there was no inhibition at concentrations
below the CC50.
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